Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Nonn, O; Debnath, O; Valdes, DS; Sallinger, K; Secener, AK; Fischer, C; Tiesmeyer, S; Nimo, J; Kuenzer, T; Ulrich, J; Maxian, T; Knöfler, M; Karau, P; Bartolomaeus, H; Kroneis, T; Frolova, A; Neuper, L; Haase, N; Malt, A; Müller-Bötticher, N; Kräker, K; Kedziora, S; Forstner, D; Eils, R; Schmidt-Ullrich, R; Haider, S; Verlohren, S; Stern, C; Sugulle, M; Jones, S; Thilaganathan, B; Kaitu'u-Lino, TJ; Tong, S; Huppertz, B; El-Heliebi, A; Staff, AC; Coscia, F; Müller, DN; Dechend, R; Gauster, M; Ishaque, N; Herse, F.
Senescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia.
Hypertension. 2025; 82(5):787-799
Doi: 10.1161/HYPERTENSIONAHA.124.23362
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Nonn Olivia
- Co-Autor*innen der Med Uni Graz
- El-Heliebi Amin
- Forstner Desiree
- Gauster Martin
- Huppertz Berthold
- Kroneis Thomas
- Kuenzer Thomas
- Neuper Lena
- Sallinger Katja
- Stern Christina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Preeclampsia is a severe hypertensive disorder in pregnancy that causes preterm delivery, maternal and fetal morbidity, mortality, and life-long sequelae. Understanding the pathogenesis of preeclampsia is a critical first step toward protecting mother and child from this syndrome and increased risk of cardiovascular disease later in life. However, effective early predictive tests and therapies for preeclampsia are scarce. METHODS: To identify novel markers and signaling pathways for early onset preeclampsia, we profiled human maternal-fetal interface units (fetal villi and maternal decidua) from early onset preeclampsia and healthy controls using single-nucleus RNA sequencing combined with spatial transcriptomics. The placental syncytiotrophoblast is in direct contact with maternal blood and forms the barrier between fetal and maternal circulation. RESULTS: We identified different transcriptomic states of the endocrine syncytiotrophoblast nuclei with patterns of dysregulation associated with a senescence-associated secretory phenotype and a spatial dysregulation of senescence in the placental trophoblast layer. Elevated senescence markers were validated in placental tissues of clinical multicenter cohorts. Importantly, several secreted senescence-associated secretory phenotype factors were elevated in maternal blood already in the first trimester. We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical preeclampsia diagnosis. CONCLUSIONS: This indicates that increased syncytiotrophoblast senescence appears weeks before clinical manifestation of early onset preeclampsia, suggesting that the dysregulated preeclamptic placenta starts with higher cell maturation resulting in premature and increased senescence-associated secretory phenotype release. These senescence-associated secretory phenotype markers may serve as an additional early diagnostic tool for this syndrome.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Female - administration & dosage
- Pregnancy - administration & dosage
- Pre-Eclampsia - metabolism, genetics, diagnosis, physiopathology
- Trophoblasts - metabolism
- Adult - administration & dosage
- Placenta - metabolism
- Plasminogen Activator Inhibitor 1 - metabolism
- Cellular Senescence - physiology
- Biomarkers - metabolism
- Transcriptome - administration & dosage
- Find related publications in this database (Keywords)
- placenta
- plasminogen activator inhibitor 1
- pre-eclampsia
- pregnancy
- pregnancy trimesters